58
Biotechnology is in a favorable environment marked by a lower 10-year US Treasury yield, a new Fed easing cycle, positive data outcomes, and renewed investor appetite. The biotech indices are up double digits year-to-date, and momentum is returning to innovation-driven names. As of October 17, the NYSE Biotechnology Index was up 17% for the year, and the S&P Select Index has risen nearly 20%. The Prudent Biotech model portfolio is up over 40% for the same period.
Cidara’s CD388 represents one of the most compelling prophylactic antivirals…